首頁 > 市場調查報告書 > 製藥

再生醫學細胞療法

細胞療法製造市場規模、佔有率、按治療類型、細胞來源、業務規模和地區進行的成長分析 - 產業預測，2025 年至 2032 年

市場調查報告書

商品編碼

1789234

細胞療法製造市場規模、佔有率、按治療類型、細胞來源、業務規模和地區進行的成長分析 - 產業預測，2025 年至 2032 年

Cell Therapy Manufacturing Market Size, Share, and Growth Analysis, By Therapy Type (T Cell Therapies, Stem Cell Therapies), By Cell Source (Autologous, Allogeneic), By Scale of Operation, By Region - Industry Forecast 2025-2032

出版日期: 2025年08月07日 | 出版商:

SkyQuest | 英文 189 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球細胞治療製造市場預計將在 2023 年達到 47.2 億美元，從 2024 年的 56.4 億美元成長到 2032 年的 248.5 億美元，在預測期內（2025-2032 年）的複合年成長率為 20.4%。

在日益成長的需求和對先進生產技術的需求的推動下，細胞療法製造格局正在迅速演變。新的生產設施正在整合自動化、封閉式生物反應器和先進的分析技術，以確保產品供應的一致性並符合監管標準。然而，該行業面臨重大挑戰，其中包括資料隱私風險，而針對合約開發和受託製造公司的網路攻擊頻頻出現。業內報告網路事件的公司比例高得驚人，凸顯了對強大的端到端資料保護的需求。此外，製造複雜性的增加導致監管審查力度加大，導致因品管問題而頻繁出現召回和合規警告。這些動態表明，在不斷擴張的市場中，創新與病患安全面臨雙重挑戰。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業市場定位（2024年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2024年）
主要企業簡介
- 公司詳情
- 產品系列分析
- 按部門分類的公司佔有率分析
- 收益同比對比（2022-2024 年）

主要企業簡介

AGC Biologics
Charles River Laboratories
FUJIFILM Cellular Dynamics
Thermo Fisher Scientific
WuXi AppTec
Lonza
Catalent
BioNTech
Cell and Gene Therapy Catapult
Cell Therapies Pty Ltd
Merck KGaA
Takara Bio
Bristol Myers Squibb
Novartis

結論和建議

簡介目錄

Product Code: SQMIG35H2356

Global Cell Therapy Manufacturing Market size was valued at USD 4.72 Billion in 2023 and is poised to grow from USD 5.64 Billion in 2024 to USD 24.85 Billion by 2032, growing at a CAGR of 20.4 % in the forecast period (2025-2032).

The cell therapy manufacturing landscape is evolving rapidly, driven by increasing demand and the need for advanced production techniques. New facilities are integrating automation, closed system bioreactors, and sophisticated analytics to ensure consistent product supply and compliance with regulatory standards. However, this sector faces significant challenges, including data privacy risks highlighted by frequent cyberattacks targeting contract development and manufacturing organizations. An alarming percentage of firms in the industry have reported cyber incidents, underscoring a critical need for robust end-to-end data protection. Moreover, heightened manufacturing complexity has resulted in more regulatory scrutiny, with frequent recalls and compliance warnings from authorities due to quality control issues. These dynamics illustrate the dual challenge of innovation and patient safety in the expanding market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell Therapy Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cell Therapy Manufacturing Market Segments Analysis

The global cell therapy manufacturing marketis segmented into therapy type, cell source, scale of operation, and region. By therapy type, the market is classified into T cell therapies, stem cell therapies, and dendritic cell therapies. Depending on the cell source, it is divided into autologous, allogeneic, and unspecified. According to scale of operation , the market is categorized into clinical and commercial. Regionally, it is analyzed across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Driver of the Global Cell Therapy Manufacturing Market

The increasing prevalence of chronic diseases such as cancer and autoimmune disorders significantly propels the global cell therapy manufacturing market. The rising number of cancer cases generates a heightened demand for advanced therapies, including CAR-T and stem cell treatments. This demand stimulates substantial investments in production technologies and innovations in scalable manufacturing solutions, empowering biotech companies to address unmet medical needs effectively. As a result, there is a concerted effort to improve market access, particularly in the fields of oncology and regenerative medicine, ensuring that cutting-edge therapies are developed and made available to a larger population of patients.

Restraints in the Global Cell Therapy Manufacturing Market

The Global Cell Therapy Manufacturing market faces significant constraints due to the intricate nature and high costs associated with the production processes. Customized treatments, such as CAR-T therapies, require specialized facilities and expert personnel, often resulting in expenses exceeding $500,000 per patient. These financial barriers restrict access, particularly in lower-income regions, and create challenges for scaling operations. Additionally, the variability in cell quality and the lengthy production timelines further complicate manufacturing processes, making it increasingly difficult for companies to establish and expand their market presence effectively. This combination of factors contributes to a restrained growth outlook for the industry.

Market Trends of the Global Cell Therapy Manufacturing Market

The Global Cell Therapy Manufacturing market is witnessing a significant trend towards the adoption of automation and closed system technologies, enhancing both efficiency and scalability in production processes. These advancements, including the utilization of robotic systems and bioreactors, are instrumental in minimizing human handling, thereby reducing contamination risks. Closed systems, particularly single-use bioreactors, ensure sterility and compliance with Good Manufacturing Practices (GMP). This technological shift not only lowers operational costs but also accelerates production timelines, especially for allogeneic therapies, allowing manufacturers to effectively meet rising demand in oncological and regenerative medicine sectors across North America and the Asia-Pacific.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technology Analysis
Case Studies
Customer Buying Behavior Analysis

Global Cell Therapy Manufacturing Market Size by Therapy Type & CAGR (2025-2032)

Market Overview
T cell therapies
Stem cell therapies
Dendritic cell therapies

Global Cell Therapy Manufacturing Market Size by Cell Source & CAGR (2025-2032)

Market Overview
Autologous
Allogeneic
Unspecified

Global Cell Therapy Manufacturing Market Size by Scale of Operation & CAGR (2025-2032)

Market Overview
Clinical
Commercial

Global Cell Therapy Manufacturing Market Size & CAGR (2025-2032)

North America (Therapy Type, Cell Source, Scale of Operation)
- US
- Canada
Europe (Therapy Type, Cell Source, Scale of Operation)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Therapy Type, Cell Source, Scale of Operation)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Therapy Type, Cell Source, Scale of Operation)
- Brazil
- Rest of Latin America
Middle East & Africa (Therapy Type, Cell Source, Scale of Operation)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

AGC Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Charles River Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
FUJIFILM Cellular Dynamics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WuXi AppTec
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lonza
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Catalent
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioNTech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cell and Gene Therapy Catapult
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cell Therapies Pty Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takara Bio
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments